Barrier-to-Design Codes for Organ-Targeted Nanomedicine: A Framework Linking Barrier Phenotypes to Nano–Bio Interface Design and Translational Validation

Abstract

Abstract Organ-targeted nanomedicine is often defined by anatomical destination, yet delivery performance is determined by the biological barriers, disease-associated remodeling, and nano–bio interface interactions encountered before therapeutically relevant cells are reached. Whole-organ accumulation, tissue fluorescence, or bulk biodistribution can demonstrate tissue arrival, but stronger targeting claims require evidence matched to the intended delivery task, including barrier crossing or penetration, spatial localization, target-cell exposure, cargo release, target engagement, functional activity, and safety. We introduce the Barrier-to-Design Codes framework, a conceptual approach that links measurable barrier phenotypes to conditional material and nano–bio interface parameters, claim-matched validation evidence, failure boundaries, and translational gates. The framework complements existing reporting, delivery-system design, and translational frameworks by treating the barrier phenotype—rather than the organ label or material class—as the primary unit of analysis. It integrates five linked domains: barrier architecture, pathological remodeling, acquired nano–bio interface behavior, including protein adsorption and immune recognition, validation, and translation. Using the blood–brain barrier, lymph nodes and immune organs, liver and metabolic organs, skin and mucosal barriers, and cartilage/extracellular-matrix niches as representative systems, we examine how particle size, charge, stiffness, ligand density, coating, release, protein adsorption, and immune recognition can acquire different functional meanings across barrier contexts. The framework separates transferable reasoning principles from non-transferable platform assumptions and requires organ-level signals to be resolved through barrier-matched models, spatial and cell-resolved exposure, pharmacokinetic/pharmacodynamic interpretation, functional response, manufacturing control, and repeat-dose safety. The Barrier-to-Design Codes framework is not a nanomaterial taxonomy, scoring system, or universal design prescription. Its intended value lies in reducing unsupported targeting claims, improving alignment between design hypotheses and validation evidence, and supporting more interpretable and translation-aware decisions, while remaining open to prospective empirical testing and refinement. Plain Language Summary Nanomedicines are very small drug-delivery systems designed to carry medicines to specific organs or tissues. Reaching an organ is an important first step, but effective delivery also requires the medicine to cross or penetrate the relevant barrier, reach the intended cells, be released at the intended site, and produce a useful effect. This review introduces “Barrier-to-Design Codes”, a practical way to connect the biological features of a barrier with the design and testing of a nanomedicine. The framework considers five linked questions: what limits access to the target tissue, how disease changes that barrier, how the nanomedicine interacts with biological fluids and cells, what evidence is needed to confirm successful delivery, and whether the product can be manufactured and used safely. The review compares several barrier systems, including the blood–brain barrier, lymph nodes, the liver, skin and mucosal tissues, and cartilage. It explains that the same particle size, surface charge, coating, or targeting ligand can behave differently in different tissues. Each organ therefore requires design choices and testing methods tailored to its particular barrier. The proposed framework encourages researchers to look beyond the total amount of a nanomedicine found in an organ and to assess where the particles are located, which cells receive the medicine, whether the treatment produces the intended effect, and whether repeated use is safe and consistent. This approach may support more reliable and clinically relevant development of organ-targeted nanomedicines. plain-language-summary Graphical Abstract The diagram illustrates three sections: Barrier phenotype, Barrier-matched nano-design and Claim-matched evidence. Barrier phenotype includes tight endothelium, immune access, sinusoidal clearance, residence/penetration and dense matrix. Barrier-matched nano-design features protein adsorption, size/stiffness, surface charge, ligand density, immune recognition, biological coating and controlled release. Claim-matched evidence involves spatial localization, target-cell exposure, cargo release, functional response and safety/manufacturing, leading to evidence-linked organ targeting. A diagram illustrating barrier phenotype, nano-design and evidence-linked organ targeting. http://www.w3.org/1999/xlink print-only float portrait IJN-21-635649-g0001.jpg anchor uf0001 portrait graphical